Search
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Benzimate
go.drugbank.com/drugs/DB05170ExperimentalIt is currently under investigation by AmpliMed and is in phase I of clinical trial. … The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's.
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalThe NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … [A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition.
Categories: Miscellaneous GI DrugsTopiroxostat
go.drugbank.com/drugs/DB01685InvestigationalWhile [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens … Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.
N-(2-Aminoethyl)-1-aziridineethanamine
go.drugbank.com/drugs/DB15643ExperimentalFirst described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease
Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamineInfluenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14587ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25mlIopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … it is still deemed to have a favorable safety profile, with only 0.7% of patients in a 2 years study experiencing adverse events.
Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamideDe Novo Triacylglycerol Biosynthesis TG(16:0/16:1(9Z)/20:0)
smpdb.ca/view/SMP0015920MetabolicAll membrane-localized enzymes are coloured dark green in the image. … Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat.
De Novo Triacylglycerol Biosynthesis TG(18:0/18:0/18:1(9Z))
smpdb.ca/view/SMP0015940MetabolicAll membrane-localized enzymes are coloured dark green in the image. … Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat.
De Novo Triacylglycerol Biosynthesis TG(18:0/20:0/20:1(11Z))
smpdb.ca/view/SMP0015945MetabolicAll membrane-localized enzymes are coloured dark green in the image. … Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat.